Policy & Regulation
-
PBMs under fire for drug prices defend their worth
A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.
By Michael Gibney • May 26, 2022 -
Q&A
The UK-based company that's striving to overcome the limitations of T cell receptor innovation
Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.
By Kim Ribbink • May 23, 2022 -
Q&A
Ironwood Pharmaceuticals is charting a course to become a giant in GI
Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market.
By Karissa Waddick • May 19, 2022 -
A potential COVID-19 EUA could turn this small biotech into a household name
Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.
By Meagan Parrish • May 19, 2022 -
Q&A
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
By Kelly Bilodeau • May 17, 2022 -
It's time to acknowledge access as a prescribing barrier
A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs.
By Karissa Waddick • May 11, 2022 -
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.
By Kelly Bilodeau • May 10, 2022 -
Profile
Laura Randa's aim to break down mental healthcare barriers for disabled patients
Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.
By Alexandra Pecci • April 27, 2022 -
Q&A
Real-world data is making drug development more true to life
How RWD is moving from the background to the spotlight in pharma’s development process.
By Kelly Bilodeau • April 26, 2022 -
Q&A
A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'
Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.
By Alexandra Pecci • April 21, 2022 -
Q&A
The cannabis vanguard: A rare disease company looks to pioneer in the space
Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.
By Jared Whitlock • April 21, 2022 -
A pharma mystery: Cancer-causing impurities drive joint search for answers
Pharmaceutical industry insiders and regulators are striving to overcome the ‘blind spots’ that contribute to nitrosamine contamination.
By Michael Gibney • April 19, 2022 -
Q&A
How pharma can up its social media game
Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities.
By Karissa Waddick • April 18, 2022 -
Sponsored by GoodRx
Inflation is forcing prioritization of healthcare spending — are you ready?
Inflation means your customers' money doesn't travel as far as it did a few weeks ago.
April 18, 2022 -
What now? Alzheimer's drugmakers ponder the path to approval
Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.
By Kelly Bilodeau • April 14, 2022 -
Q&A
Biotech goes Hollywood
A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.
By Taren Grom • April 13, 2022 -
How Congress could play a role in personalized medicine
PGx — a tool to help determine proper dosing — may be poised to achieve broader use in healthcare and pharma.
By Kelly Bilodeau • April 11, 2022 -
Q&A
Down but not out: How AVEO's CEO steered the company past an FDA rejection
Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.
By Kim Ribbink • April 5, 2022 -
Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up
A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.
By Kelly Bilodeau • March 23, 2022 -
Virpax's CEO on leveraging new formulations to move drugs toward approval
Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.
By Meagan Parrish • March 18, 2022 -
Q&A
Clearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
By Kim Ribbink • March 14, 2022 -
Q&A
Ultragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
By Kim Ribbink • March 9, 2022 -
Profile
From angel to operator: The unlikely journey of Endevica Bio's CEO
Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.
By Jared Whitlock • March 9, 2022 -
QSAM's rare cancer treatment could be a game-changer
For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.
By Alexandra Pecci • Feb. 17, 2022 -
Welcome to the new PharmaVoice
A similar mission, a new format, and our plans for PharmaVoice's next chapter.
By Davide Savenije • Jan. 13, 2022